IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.8701
-0.0866 (-9.05%)
At close: Oct 30, 2026, 4:00 PM EDT
0.9390
+0.0689 (7.92%)
After-hours: Oct 30, 2026, 7:27 PM EDT
IceCure Medical Employees
As of December 31, 2025, IceCure Medical had 69 total employees, including 67 full-time and 2 part-time employees. The number of employees increased by 3 or 4.55% compared to the previous year. That makes IceCure Medical the 33,583rd largest employer in the world and 4,407th in the United States.
Employees
69
Change (1Y)
3
Growth (1Y)
4.55%
Revenue / Employee
$57,203
Profits / Employee
-$244,638
Market Cap
4.04M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 69 | 3 | 4.55% | 67 | 2 |
| Dec 31, 2024 | 66 | -11 | -14.29% | 64 | 2 |
| Dec 31, 2023 | 77 | 5 | 6.94% | 71 | 6 |
| Dec 31, 2022 | 72 | 8 | 12.50% | 65 | 7 |
| Dec 31, 2021 | 64 | 17 | 36.17% | 55 | 9 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Trinity Biotech | 287 |
| Baird Medical Investment Holdings | 146 |
| Co-Diagnostics | 115 |
| Intelligent Bio Solutions | 60 |
| VolitionRx | 57 |
| enVVeno Medical | 33 |
| 20/20 Biolabs | 14 |
| Autonomix Medical | 11 |
ICCM News
- 4 days ago - IceCure Medical completes first cryoablation treatment in breast-cancer study - TheFly
- 4 days ago - IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation - PRNewsWire
- 11 days ago - IceCure Medical begins enrollment in ProSense breast cancer cryoablation study - TheFly
- 11 days ago - IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites - PRNewsWire
- 18 days ago - IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026 - PRNewsWire
- 25 days ago - IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site - PRNewsWire
- 4 weeks ago - IceCure Medical management to meet with Lake Street - TheFly
- 7 weeks ago - IceCure Medical granted regulatory approval to market ProSense in China - TheFly